Uncovering improper billing in urine drug screens
Improper billing practices and schemes associated to urine drug screens (UDS) are widespread, requiring investigative sources to detect potential fraud, waste, and abuse (FWA). Although the Facilities for Medicare & Medicaid Companies (CMS) regulates human lab samples by way of strict tips outlined within the required Medical Laboratory Enhancements Amendments (CLIA) certification, some laboratories and
Uncovering improper billing in urine drug screens Read More »









